S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Adenocarcinoma * No component of squamous cell carcinoma present * Incompletely resected or unresectable disease * Stage IIIB or IV disease as defined below: * Selected stage IIIB disease * T4 (cytologically confirmed malignant pleural effusion OR pleural tumor foci that are separate from direct pleural invasion by the primary tumor) * Any N * M0 * Stage IV disease * Any T * Any N * M1 (distant metastases present) * Recurrent lung cancer in a separate lobe after resection or radiotherapy within the past 5 years OR multifocal lesions in \> 1 lobe considered stage IV disease * New lesions occurring ≥ 5 years after resection may be considered a separate primary cancer and are not allowed if this is the only focus of lung cancer * Measurable and/or nonmeasurable disease by CT scan, positron emission tomography scan, or MRI * Disease must be present outside a previous radiotherapy field OR a new lesion must be inside the port * Measurable disease must be assessed within the past 28 days * Nonmeasurable disease must be assessed within the past 42 days * Pleural effusions, ascites, and laboratory parameters are not acceptable as the only evidence of disease * Must be a lifelong nonsmoker (\< 100 cigarettes in lifetime) * Treated brain metastases allowed provided the patient is asymptomatic and do not require steroids PATIENT CHARACTERISTICS: * Zubrod performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Total bilirubin normal * SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present) * Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if bone metastases present) * Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min * Urine protein:creatinine ratio ≤ 0.5 OR urine protein \< 1,000 mg by 24-hour urine collection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Hypertension allowed if controlled on medication prior to study enrollment * Must be willing to provide prior smoking history * No immediate life-threatening complications from malignancies * No prior major medical condition, psychological condition, or social situation that would preclude study treatment * No hemoptysis ≥ ½ teaspoon within the past 28 days * No clinical history of pulmonary or upper respiratory hemorrhage ≥ grade 2 within the past 6 months or grade 1 within the past 28 days * No history of either thrombosis or hemorrhage, including hemorrhagic or thrombotic stroke, or other CNS bleeding * No serious nonhealing wound, ulcer, or bone fracture * No other prior malignancy except for the following: * Adequately treated basal cell or squamous cell skin cancer * Adequately treated stage I or II cancer from which the patient is currently in complete remission * In situ cervical cancer * Any other cancer from which the patient has been disease-free for 5 years PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 7 days since prior fine-needle aspiration or core biopsy * At least 28 days since prior radiotherapy (14 days for palliative radiotherapy) and recovered * At least 28 days since prior surgery (e.g., thoracic or other major surgeries) and recovered * At least 28 days since prior systemic chemotherapy * Prior biologic therapy allowed * No prior gefitinib, erlotinib hydrochloride, bevacizumab, or other targeted therapies against the epidermal growth factor receptor or vascular endothelial growth factor axes * Concurrent stable, therapeutic anticoagulation therapy allowed (e.g., warfarin or low molecular weight heparin), provided the patient has no history of bleeding complications on anticoagulation or an inability to establish a stable therapeutic regimen for anticoagulation * No concurrent surgery * No other concurrent nonprotocol treatment (including chemotherapy, hormonal therapy, biological therapy, or radiotherapy) directed at this cancer